These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 15477584)

  • 21. The Role of Monoamine Oxidase B Inhibitors in the Treatment of Parkinson's Disease - An Update.
    Chew ZX; Lim CL; Ng KY; Chye SM; Ling APK; Koh RY
    CNS Neurol Disord Drug Targets; 2023; 22(3):329-352. PubMed ID: 34970960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
    Chen JJ; Fernandez HH
    Drugs Aging; 2007; 24(8):663-80. PubMed ID: 17702535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease.
    Jost WH
    J Neural Transm (Vienna); 2022 Jun; 129(5-6):723-736. PubMed ID: 35107654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selegiline, pregnancy, and Parkinson's disease.
    Kupsch A; Oertel WH
    Mov Disord; 1998 Jan; 13(1):175-6. PubMed ID: 9452347
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.
    Jost WH; Friede M; Schnitker J
    Eur Rev Med Pharmacol Sci; 2014 Nov; 18(22):3349. PubMed ID: 25491607
    [No Abstract]   [Full Text] [Related]  

  • 26. MAO-B inhibitors in Parkinson's disease.
    Olanow CW
    Adv Neurol; 1993; 60():666-71. PubMed ID: 8420207
    [No Abstract]   [Full Text] [Related]  

  • 27. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
    Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
    J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A scientific rationale for protective therapy in Parkinson's disease.
    Olanow CW
    J Neural Transm Gen Sect; 1993; 91(2-3):161-80. PubMed ID: 8512683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Experience using selective monoamine oxidase inhibitors in treating parkinsonism patients].
    Stoliarova LG; Kadykov AS; Shvedkov VV; Shakhparonova NV
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1988; 88(12):11-3. PubMed ID: 3149842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The advent of selective monoamine oxidase A inhibitor antidepressants devoid of the cheese reaction.
    Youdim MB
    Acta Psychiatr Scand Suppl; 1995; 386():5-7. PubMed ID: 7717095
    [No Abstract]   [Full Text] [Related]  

  • 34. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.
    Clarke A; Johnson ES; Mallard N; Corn TH; Johnston A; Boyce M; Warrington S; MacMahon DG
    J Neural Transm (Vienna); 2003 Nov; 110(11):1257-71. PubMed ID: 14628190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoamine oxidase inhibitor efficacy in depression and the "cheese effect".
    Sandler M
    Psychol Med; 1981 Aug; 11(3):455-8. PubMed ID: 6791195
    [No Abstract]   [Full Text] [Related]  

  • 36. Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline.
    Degli Esposti L; Piccinni C; Sangiorgi D; Nobili F; Buda S
    Neurol Sci; 2016 Feb; 37(2):227-34. PubMed ID: 26474874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoamine oxidase inhibitors. A perspective on their use in the elderly.
    Volz HP; Gleiter CH
    Drugs Aging; 1998 Nov; 13(5):341-55. PubMed ID: 9829163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoamine Oxidase B Inhibitors in Parkinson's Disease.
    Dezsi L; Vecsei L
    CNS Neurol Disord Drug Targets; 2017; 16(4):425-439. PubMed ID: 28124620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease.
    Ito D; Amano T; Sato H; Fukuuchi Y
    J Neurol; 2001 Jun; 248(6):533-4. PubMed ID: 11499649
    [No Abstract]   [Full Text] [Related]  

  • 40. Monoamine oxidase inhibitors as anti-depressant drugs and as adjunct to L-dopa therapy of Parkinson's disease.
    Youdim MB
    J Neural Transm Suppl; 1980; (16):157-61. PubMed ID: 6107329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.